Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Headlands Technologies LLC

Headlands Technologies LLC lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 203.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,515 shares of the specialty pharmaceutical company’s stock after buying an additional 1,015 shares during the quarter. Headlands Technologies LLC’s holdings in Supernus Pharmaceuticals were worth $55,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Exchange Traded Concepts LLC raised its position in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after buying an additional 560 shares during the last quarter. HighTower Advisors LLC increased its stake in shares of Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after acquiring an additional 624 shares during the period. Bridge City Capital LLC raised its holdings in Supernus Pharmaceuticals by 0.8% during the fourth quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company’s stock worth $3,435,000 after purchasing an additional 761 shares in the last quarter. Rhumbline Advisers raised its holdings in Supernus Pharmaceuticals by 0.5% during the fourth quarter. Rhumbline Advisers now owns 172,444 shares of the specialty pharmaceutical company’s stock worth $6,236,000 after purchasing an additional 800 shares in the last quarter. Finally, Swiss National Bank lifted its position in Supernus Pharmaceuticals by 0.7% in the fourth quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company’s stock valued at $3,920,000 after purchasing an additional 800 shares during the period.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,104 shares of company stock valued at $440,263 in the last quarter. 9.30% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SUPN shares. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, April 1st.

Supernus Pharmaceuticals Trading Down 1.4 %

Shares of SUPN opened at $32.27 on Tuesday. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The firm has a market capitalization of $1.80 billion, a P/E ratio of 30.16 and a beta of 0.90. The firm’s 50-day moving average is $34.42 and its two-hundred day moving average is $35.08.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.